AAAAAA
Results:
1-11
|
Results: 11
Authors:
Follen, M
Meyskens, FL
Atkinson, EN
Schottenfeld, D
Citation: M. Follen et al., Why most randomized phase II cervical cancer chemoprevention trials are uninformative: Lessons for the future, J NAT CANC, 93(17), 2001, pp. 1293-1296
Authors:
Nishizaki, M
Meyn, RE
Levy, LB
Atkinson, EN
White, RA
Roth, JA
Ji, L
Citation: M. Nishizaki et al., Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo, CLIN CANC R, 7(9), 2001, pp. 2887-2897
Authors:
Follen, M
Atkinson, EN
Schottenfeld, D
Malpica, A
West, L
Lippman, S
Zou, CP
Hittelman, WN
Lotan, R
Hong, WK
Citation: M. Follen et al., A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix, CLIN CANC R, 7(11), 2001, pp. 3356-3365
Authors:
Hoque, A
Lippman, SM
Boiko, IV
Atkinson, EN
Sneige, N
Sahin, A
Weber, DM
Risin, S
Lagios, MD
Schwarting, P
Colburn, WJ
Dhingra, K
Follen, M
Kelloff, GJ
Boone, CW
Hittelman, WN
Citation: A. Hoque et al., Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast, CANC EPID B, 10(3), 2001, pp. 249-259
Authors:
Verschraegen, CF
Benjapibal, M
Supakarapongkul, W
Levy, LB
Ross, M
Atkinson, EN
Bodurka-Bevers, D
Kavanagh, JJ
Kudelka, AP
Legha, SS
Citation: Cf. Verschraegen et al., Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later, INT J GYN C, 11(5), 2001, pp. 359-364
Authors:
Freedman, RS
Kudelka, AP
Kavanagh, JJ
Verschraegen, C
Edwards, CL
Nash, M
Levy, L
Atkinson, EN
Zhang, HZ
Melichar, B
Patenia, R
Templin, S
Scott, W
Platsoucas, CD
Citation: Rs. Freedman et al., Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma, CLIN CANC R, 6(6), 2000, pp. 2268-2278
Authors:
Verschraegen, CF
Sittisomwong, T
Kudelka, AP
Guedes, ED
Steger, M
Nelson-Taylor, T
Vincent, M
Rogers, R
Atkinson, EN
Kavanagh, JJ
Citation: Cf. Verschraegen et al., Docetaxel for patients with paclitaxel-resistant mullerian carcinoma, J CL ONCOL, 18(14), 2000, pp. 2733-2739
Authors:
Fornage, BD
Atkinson, EN
Nock, LF
Jones, PH
Citation: Bd. Fornage et al., US with extended field of view: Phantom-tested accuracy of distance measurements, RADIOLOGY, 214(2), 2000, pp. 579-584
Authors:
Gordinier, ME
Zhang, HZ
Patenia, R
Levy, LB
Atkinson, EN
Nash, MA
Katz, RL
Platsoucas, CD
Freedman, RS
Citation: Me. Gordinier et al., Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma, CLIN CANC R, 5(9), 1999, pp. 2498-2505
Authors:
Utzinger, U
Trujillo, EV
Atkinson, EN
Mitchell, MF
Cantor, SB
Richards-Kortum, R
Citation: U. Utzinger et al., Performance estimation of diagnostic tests for cervical precancer based onfluorescence spectroscopy: Effects of tissue type, sample size, population, and signal-to-noise ratio, IEEE BIOMED, 46(11), 1999, pp. 1293-1303
Authors:
Gershenson, DM
Morris, M
Burke, TW
Levenback, C
Wolf, J
Lee, JJ
Thall, PF
Atkinson, EN
Silva, EG
Wharton, JT
Citation: Dm. Gershenson et al., A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma, CANCER, 86(11), 1999, pp. 2291-2300
Risultati:
1-11
|